AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01701531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBCPF
Study NCT03775733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Red Ginseng Extract
Description: Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
Study NCT02665104 — intervention group
Intervention type: DEVICE
Intervention: transcranial Doppler (TCD) and INVOS monitor
Description: Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
Study NCT03775733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study NCT04143828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile mindfulness programme
Description: The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience.
Study NCT03657225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Utilization of the mini CPB circuit
Description: Comparison of the mini CPB circuit to conventional circuit
Study NCT03657225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Utilization of the conventional circuit
Description: Comparison of the mini CPB circuit to conventional circuit
Study NCT01160328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leuprolide
Description: 7.5 mg - 1 month depot, 2 doses over 7 weeks
Study NCT01160328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg - 1 month depot, 2 doses over 7 weeks
Study NCT01785823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D6-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study NCT01160328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: 7.5g - 1% testosterone gel, daily x 7 weeks
Study NCT01045668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Catheter Ablation (RFCA)
Description: RFCA of clinical VT
Study NCT01045668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Catheter Ablation (RFCA)
Description: RFCA of clinical VT as well as VT substrates
Study NCT03647085 — intervention group
Intervention type: DEVICE
Intervention: Wearable cardiac monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
Study NCT01785823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D6-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study NCT01785823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D8-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study NCT01785823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D8-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study NCT02702414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT01950312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Study NCT04137250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring
Description: The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
Study NCT03602209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of infected implant
Study NCT03602209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of infected implant
Study NCT00510354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Study NCT04137250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon
Description: orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
Study NCT03390309 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Partially Hydrolyzed Formula
Description: Partially Hydrolyzed Whey Protein Infant Formula
Study NCT00559546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
Study NCT03390309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Formula
Description: Normal Formula
Study NCT06583746 — intervention group
Intervention type: OTHER
Intervention: Group1
Description: 30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
Study NCT01646242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of eligible polyps using cold snare polypectomy technique
Description: Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
Study NCT01646242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of eligible polyps using double biopsy technique
Description: Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
Study NCT00383942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol,25 micrograms every 4 hours.
Study NCT00383942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
Study NCT01936415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard
Description: A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
Study NCT01936415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenerex
Study NCT00741403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
Study NCT01852812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Granules (OG)
Description: Montelukast 4 mg in one sachet
Study NCT01852812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Chewable Tablets (CT)
Description: Montelukast 5 mg in one tablet
Study NCT02567006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS message
Description: SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
Study NCT02567006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Health clinic nurse provides regular appointment in the vaccination card with no active reminders
Study NCT01684371 — intervention group
Intervention type: OTHER
Intervention: Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)
Description: Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
Study NCT01425554 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Doppler sonography of internal jugular veins
Description: Doppler sonography of internal jugular veins
Study NCT01425554 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Magnetic resonance venography of internal jugular veins
Description: Magnetic resonance venography of internal jugular veins
Study NCT01425554 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Air-plethysmography of the neck
Description: Air-plethysmography of the neck
Study NCT01425554 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Catheter venography of internal jugular veins
Description: Catheter venography of internal jugular veins
Study NCT02596269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
Study NCT02596269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
Study NCT03602209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic durations
Study NCT03602209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic durations
Study NCT00556309 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
Study NCT03136809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: copper-containing synthetic small molecule
Study NCT02957500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore® (adhesion barrier)
Study NCT03350360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
Study NCT03350360 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Training
Description: Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
Study NCT03350360 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison Task
Description: Neutral- neutral stimuli prior to response task
Study NCT03966755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UFA dietary recommendations
Description: The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
Study NCT00821470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: core decompression procedure only
Study NCT00821470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: core decompression procedure only
Study NCT00821470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow implantation into the necrotic lesion
Study NCT03096327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
Study NCT03096327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
Study NCT01310426 — intervention group
Intervention type: OTHER
Intervention: 3D transperineal Ultrasound
Description: 3D transperineal Ultrasound after vaginal delivery
Study NCT00060333 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02764684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
Study NCT04180566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound Examination
Description: Includes a regular growth ultrasound examination.
Study NCT04180566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antenatal Testing (biophysical profile)
Description: Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
Study NCT03612765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push-Pull-Hold Program
Description: Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
Study NCT02337634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Study NCT02337634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milk Thistle
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Study NCT04877236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Sun Medical Brace
Description: All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board.
Study NCT01858649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
Study NCT01858649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
Study NCT03221309 — intervention group
Intervention type: OTHER
Intervention: Evaluate model of care for HCV-infected adults with on-going opioid misuse
Description: Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
Study NCT03306329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNS-7801 (low-dose)
Description: DNS-7801 (low-dose) tablets administered once daily.
Study NCT03306329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNS-7801 (high dose)
Description: DNS-7801 (high dose) tablets administered once daily.
Study NCT04437524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
Study NCT00743639 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intramyocardial bone marrow stem cells implantation
Description: Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days.
Study NCT02744963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free and convenient medicine access
Study NCT02300922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody TF2
Description: injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
Study NCT02300922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90-Y-IMP-288
Description: Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
Study NCT02300922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-IMP-288
Description: Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
Study NCT02573142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bull City Healthy and Fit
Description: Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.